Literature DB >> 1792560

Distributions of hallucinations in the population.

A Y Tien1.   

Abstract

Hallucinations are often manifestations of severe psychiatric conditions seen clinically. However, little is known about the distribution of incident hallucinations in the community, nor whether there has been a change over the past century. Data from the NIMH Epidemiologic Catchment Area Program is used here to provide descriptive information on the community distribution, and data from the Sidgewick study from a century earlier provides comparative information. In the ECA data, the incidence of visual hallucinations was slightly higher in males (about 20 per 1000 per year) than females (about 13 per 1000 per year) across the age span from 18 to 80 years old, with a subsequent increase in the rate for females (up to about 40 per 1000 per year) after age 80. For auditory hallucinations there was an age 25-30 peak in males with a trough for females, and a later age 40-50 peak for females. Overall, there were substantial gender differences, and the effect of aging to increase the incidence of hallucinations was the most consistent and prominent. The Sidgewick study showed a much higher proportion of visual hallucinations than the ECA program. This might be due to factors affecting brain function as well as social and psychological changes over time, although methodological weaknesses in both studies might also be responsible.

Entities:  

Mesh:

Year:  1991        PMID: 1792560     DOI: 10.1007/bf00789221

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  12 in total

Review 1.  Schizotaxia revisited.

Authors:  P E Meehl
Journal:  Arch Gen Psychiatry       Date:  1989-10

2.  The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program.

Authors:  W W Eaton; M Kramer; J C Anthony; A Dryman; S Shapiro; B Z Locke
Journal:  Acta Psychiatr Scand       Date:  1989-02       Impact factor: 6.392

3.  Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception.

Authors:  A Burns; R Jacoby; R Levy
Journal:  Br J Psychiatry       Date:  1990-07       Impact factor: 9.319

4.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

Authors:  L N Robins; J E Helzer; J Croughan; K S Ratcliff
Journal:  Arch Gen Psychiatry       Date:  1981-04

5.  Occupational characteristics and the occurrence of psychotic disorders.

Authors:  C Muntaner; A Y Tien; W W Eaton; R Garrison
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1991-12       Impact factor: 4.328

6.  Psychosocial issues.

Authors:  M J Goldstein
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

7.  Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type.

Authors:  J L Cummings; B Miller; M A Hill; R Neshkes
Journal:  Arch Neurol       Date:  1987-04

8.  Sex differences in age at first hospital admission for schizophrenia: fact or artifact?

Authors:  R R Lewine; J S Strauss; T E Gift
Journal:  Am J Psychiatry       Date:  1981-04       Impact factor: 18.112

Review 9.  Hallucinations: theoretical and clinical overview.

Authors:  G Asaad; B Shapiro
Journal:  Am J Psychiatry       Date:  1986-09       Impact factor: 18.112

10.  Delusions and the psychopathology of the elderly with dementia.

Authors:  G E Berrios; P Brook
Journal:  Acta Psychiatr Scand       Date:  1985-09       Impact factor: 6.392

View more
  74 in total

Review 1.  Late-onset schizophrenia: epidemiology, diagnosis, management and outcomes.

Authors:  P A Wynn Owen; D J Castle
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 2.  Religion, spirituality, and psychosis.

Authors:  Adair Menezes; Alexander Moreira-Almeida
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

3.  Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.

Authors:  Oliver D Howes; Paul Shotbolt; Michael Bloomfield; Kirstin Daalman; Arsime Demjaha; Kelly M J Diederen; Kemal Ibrahim; Euitae Kim; Philip McGuire; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

4.  Social defeat and the culture of chronicity: or, why schizophrenia does so well over there and so badly here.

Authors:  T M Luhrmann
Journal:  Cult Med Psychiatry       Date:  2007-06

5.  A survey of psychosis risk symptoms in Kenya.

Authors:  Daniel Mamah; Anne Mbwayo; Victoria Mutiso; Deanna M Barch; John N Constantino; Thelma Nsofor; Lincoln Khasakhala; David M Ndetei
Journal:  Compr Psychiatry       Date:  2011-09-25       Impact factor: 3.735

6.  Affective processes in the onset and persistence of psychosis.

Authors:  Lydia Krabbendam; Jim van Os
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

7.  Treatment of auditory verbal hallucinations with transcranial magnetic stimulation in a patient with psychotic major depression: one-year follow-up.

Authors:  Catarina Freitas; Chester Pearlman; Alvaro Pascual-Leone
Journal:  Neurocase       Date:  2011-06-28       Impact factor: 0.881

8.  Network analysis of auditory hallucinations in nonpsychotic individuals.

Authors:  Remko van Lutterveld; Kelly M J Diederen; Willem M Otte; Iris E Sommer
Journal:  Hum Brain Mapp       Date:  2013-02-21       Impact factor: 5.038

9.  Semantic expectations can induce false perceptions in hallucination-prone individuals.

Authors:  Ans Vercammen; André Aleman
Journal:  Schizophr Bull       Date:  2008-06-17       Impact factor: 9.306

10.  Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study.

Authors:  Scott W Woods; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Robert Heinssen; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2009-04-21       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.